Cyclerion Therapeutics, Inc.CYCNEarnings & Financial Report
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for serious neurodegenerative, rare, and cardiometabolic diseases with high unmet medical need. Its pipeline leverages soluble guanylate cyclase modulation science to serve underserved patient populations across global markets.
CYCN Q4 FY2025 Key Financial Metrics
Revenue
$1.0M
Gross Profit
N/A
Operating Profit
$-838.0K
Net Profit
$-799.0K
Gross Margin
N/A
Operating Margin
-81.8%
Net Margin
-78.0%
YoY Growth
-43.2%
EPS
$-0.14
Cyclerion Therapeutics, Inc. Q4 FY2025 Financial Summary
Cyclerion Therapeutics, Inc. reported revenue of $1.0M (down 43.2% YoY) for Q4 FY2025, with a net profit of $-799.0K (down 250.8% YoY) (-78.0% margin).
Key Financial Metrics
| Total Revenue | $1.0M |
|---|---|
| Net Profit | $-799.0K |
| Gross Margin | N/A |
| Operating Margin | -81.8% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
Cyclerion Therapeutics, Inc. Q4 FY2025 revenue of $1.0M breaks down across 2 segments, led by License Agreement at $1.0M (97.6% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| License Agreement | $1.0M | 97.6% |
| Other | $25.0K | 2.4% |
Cyclerion Therapeutics, Inc. Revenue by Segment — Quarterly Trend
Cyclerion Therapeutics, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as License Agreement and Other) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q4 FY2024 | Q2 FY2024 |
|---|---|---|---|---|
| License Agreement | $1.0M | — | $1.8M | — |
| Other | $25.0K | — | $56.0K | — |
Cyclerion Therapeutics, Inc. Annual Revenue by Year
Cyclerion Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2023 revenue was $0).
Cyclerion Therapeutics, Inc. Quarterly Revenue & Net Profit History
Cyclerion Therapeutics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $1.0M | -43.2% | $-799.0K | -78.0% |
| Q3 FY2025 | $875.0K | +351.0% | $-976.0K | -111.5% |
| Q4 FY2024 | $1.8M | — | $530.0K | 29.3% |
| Q2 FY2024 | $0 | — | $-1.3M | N/A |
| Q1 FY2024 | $0 | — | $-1.5M | N/A |
| Q4 FY2023 | $0 | — | $-1.7M | N/A |
| Q3 FY2023 | $0 | — | $7.6M | N/A |
| Q2 FY2023 | $0 | — | $-4.2M | N/A |
Income Statement
| Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q4 2024 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $1.8M | $875000 | $1.0M |
| YoY Growth | N/A | N/A | N/A | N/A | N/A | N/A | 351.0% | -43.2% |
Balance Sheet
| Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q4 2024 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $10.1M | $15.2M | $13.4M | $11.4M | $10.1M | $9.6M | $10.4M | $10.0M |
| Liabilities | $4.9M | $2.3M | $2.1M | $1.4M | $1.3M | $725000 | $877000 | $900000 |
| Equity | $5.2M | $12.9M | $11.3M | $9.9M | $8.8M | $8.8M | $9.5M | $9.1M |
Cash Flow
| Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q4 2024 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-6.6M | $-6.9M | $-1.5M | $-1.9M | $-1.1M | $360000 | $-264000 | $-1.6M |